JP2023527612A5 - - Google Patents

Info

Publication number
JP2023527612A5
JP2023527612A5 JP2022551351A JP2022551351A JP2023527612A5 JP 2023527612 A5 JP2023527612 A5 JP 2023527612A5 JP 2022551351 A JP2022551351 A JP 2022551351A JP 2022551351 A JP2022551351 A JP 2022551351A JP 2023527612 A5 JP2023527612 A5 JP 2023527612A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
pain
cbga
immune cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022551351A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023527612A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/019474 external-priority patent/WO2021173718A1/en
Publication of JP2023527612A publication Critical patent/JP2023527612A/ja
Publication of JP2023527612A5 publication Critical patent/JP2023527612A5/ja
Pending legal-status Critical Current

Links

JP2022551351A 2020-02-25 2021-02-24 カンナビノイド組成物 Pending JP2023527612A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062981424P 2020-02-25 2020-02-25
US62/981,424 2020-02-25
US202063072806P 2020-08-31 2020-08-31
US63/072,806 2020-08-31
PCT/US2021/019474 WO2021173718A1 (en) 2020-02-25 2021-02-24 Cannabinoid compositions

Publications (2)

Publication Number Publication Date
JP2023527612A JP2023527612A (ja) 2023-06-30
JP2023527612A5 true JP2023527612A5 (cg-RX-API-DMAC7.html) 2024-03-04

Family

ID=77490171

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022551351A Pending JP2023527612A (ja) 2020-02-25 2021-02-24 カンナビノイド組成物

Country Status (6)

Country Link
US (1) US20230091336A1 (cg-RX-API-DMAC7.html)
EP (1) EP4110045A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023527612A (cg-RX-API-DMAC7.html)
AU (1) AU2021227227A1 (cg-RX-API-DMAC7.html)
CA (1) CA3172868A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021173718A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202101732D0 (en) * 2021-02-08 2021-03-24 Tts Pharma Ltd A cannabinoid mixture
WO2023064478A1 (en) * 2021-10-13 2023-04-20 Portland Technology Holdings Llc Hemp extract for treatment of pain, cancer and epilepsy in animals
US12440454B2 (en) 2022-02-01 2025-10-14 Portland Technology Holdings Llc Pharmaceutical compositions containing hemp extract for administration to felines and related methods
WO2026038872A1 (ko) * 2024-08-13 2026-02-19 주식회사 네오켄바이오 신규한 화합물 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1559423A1 (en) * 2004-02-02 2005-08-03 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Medicinal acidic cannabinoids
GB2527590A (en) * 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
JP7225104B2 (ja) * 2017-02-01 2023-02-20 ジービーエス グローバル バイオファーマ,インコーポレイテッド マスト細胞関連炎症障害又は好塩基球媒介炎症障害の治療のためのカンナビノイド含有複合混合物
WO2018163164A1 (en) * 2017-03-05 2018-09-13 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Compositions and methods for treating cancer
JP2020520966A (ja) * 2017-05-22 2020-07-16 ジービーエス グローバル バイオファーマ,インコーポレイテッド Trpv1を標的にするミルセン及びカンナビノイド含有組成物
WO2019071302A1 (en) * 2017-10-09 2019-04-18 The University Of Sydney METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING EPILEPSY CRISES
US10751380B2 (en) * 2018-03-08 2020-08-25 Alexander Kariman Compound and method for treating spasms, inflammation and pain
CA3096842A1 (en) * 2018-04-09 2019-10-17 Ellevet Sciences Hemp extract for treatment of pain in animals
CN112543633A (zh) * 2018-05-22 2021-03-23 Gbs全球生物制药公司 Trpv1调节中使用的大麻素和/或萜烯
EP3813823A4 (en) * 2018-06-28 2022-08-10 Canopy Growth Corporation COMPOSITIONS AND METHODS FOR AGONIZING THE CB2 RECEPTOR

Similar Documents

Publication Publication Date Title
ARAKAWA et al. Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing
Henrotin et al. Natural products for promoting joint health and managing osteoarthritis
Selim et al. Fucoidan mitigates gastric ulcer injury through managing inflammation, oxidative stress, and NLRP3-mediated pyroptosis
Ordooei Javan et al. A review on colistin nephrotoxicity
Morgera et al. Pilot study on the effects of high cutoff hemofiltration on the need for norepinephrine in septic patients with acute renal failure
Zhou et al. Curcumin inhibits placental inflammation to ameliorate LPS-induced adverse pregnancy outcomes in mice via upregulation of phosphorylated Akt
US20050147675A1 (en) Composition for the treatment and prevention of endothelial dysfunction
Gunasekaran et al. Hyaluronan 35 kDa enhances epithelial barrier function and protects against the development of murine necrotizing enterocolitis
Ma et al. Thiamine alleviates high-concentrate-diet-induced oxidative stress, apoptosis, and protects the rumen epithelial barrier function in goats
Bak et al. Effects of dietary supplementation of glucosamine sulfate on intestinal inflammation in a mouse model of experimental colitis
KR20190095937A (ko) 설페이트화된 다당류를 포함하는 조성물
Wang et al. Florfenicol induces renal toxicity in chicks by promoting oxidative stress and apoptosis
Zhou et al. Supplementation of the diet with Salecan attenuates the symptoms of colitis induced by dextran sulphate sodium in mice
Raj et al. The effects of oat ingredients on blood pressure in spontaneously hypertensive rats
Motavallian et al. An investigation of the anti-inflammatory effects of gabapentin on acetic acid-induced colitis in rats
AU2025234176A1 (en) Treatment for Coronavirus infection and associated cytokine toxicity
Li et al. Simvastatin attenuates acute lung injury by activation of A2B adenosine receptor
Kim et al. BN82002 alleviated tissue damage of septic mice by reducing inflammatory response through inhibiting AKT2/NF-κB signaling pathway
JP2022521711A5 (cg-RX-API-DMAC7.html)
US20120244226A1 (en) Treatment composition and method
WO2021195691A1 (en) Methods and compositions for treating or preventing an inflammatory condition
Ecelbarger et al. The effect of chronic candesartan therapy on the metabolic profile and renal tissue cytokine levels in the obese Zucker rat
Cahyawati Effect of simvastatin on histopathology of the heart after 5/6 subtotal nephrectomy
US20240050455A1 (en) Methods of treatment of a cytokine storm
Yao et al. Peroxisome proliferator-activated receptor-γ agonists diminish peritoneal functional and morphological changes induced by bioincompatible peritoneal dialysis solution